After nearly three decades in Germany, the doors to MorphoSys US opened in 2019 in Boston to launch of our first breakthrough cancer immunotherapy.
Since then, we haven’t slowed down. Adding to our leading R&D capabilities in Germany, a second global development hub opened in Boston to accelerate our global drug development capabilities. In 2021, we expanded our portfolio with the acquisition of Constellation Pharmaceuticals and are an emerging leader and future powerhouse in hematology-oncology. Grow with us.